Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2025.Sep.01

Press Conference on Material Information Regarding the Board Resolution for Capital Reduction to Offset Accumulated Losses

2025.Sep.01

The Company’s Board of Directors resolved to conduct a capital reduction to offset accumulated losses.

2025.Sep.01

The Company’s Board of Directors resolved to convene the 2025 first extraordinary general shareholders’ meeting

2025.Aug.26

Announcement for OBIGEN that its Phase 2 study for OBI-858 received positive final results and met primary and secondary endpoints with statistical significance

2025.Aug.22

Announcement on behalf of OBIGEN:TFDA Approves IND application for Two Pivotal Phase III Studies of OBI-858

2025.Aug.11

Announcement of the Consolidated Financial Statements for the second quarter of 2025 were approved by the Board of Directors

2025.Jul.31

Announcement for the expected date of the Board of Directors Meeting for 2025Q2 consolidated financial report is 2025/08/11

2025.Jul.28

Announcement on behalf of OBIGEN Pharma of the BOD’s resolution to lift the non-competition restrictions for CEO

2025.Jul.18

OBI-902 TROP2 ADC has been granted by the TFDA to proceed to Phase I/II human clinical trial

2025.Jun.27

Announcement of 1st Sustainable Development Committee Members

News

Latest News

Events

Latest events